VIVUS,INC. (NASDAQ:VVUS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

VIVUS,INC. (NASDAQ:VVUS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Story continues below

On October26, 2018, the Board of Directors, or the Board, of VIVUS,Inc., or the Company, appointed Karen Ferrell and Edward R. Kangas as directors of the Company. The Board has determined that Ms.Ferrell and Mr.Kangas are independent of the Company and its management under the standards set forth by the Securities and Exchange Commission and the applicable Nasdaq Listing Rules. There were not any arrangements or understandings between Ms.Ferrell or Mr.Kangas and any other persons to which they were elected as directors. There are no family relationships between Ms.Ferrell or Mr.Kangas and any director or executive officer of the Company, and they have no direct or indirect material interest in any transaction required to be disclosed to Item 404(a)of Regulation S-K. Ms.Ferrell and Mr.Kangas’s compensation is expected to be consistent with that provided to all of the Company’s non-employee directors, as described in the Company’s Definitive Proxy Statement on FormDEF 14A filed with the Securities and Exchange Commission on August1, 2018 (the share numbers in such description have not been adjusted for the 1-for-10 reverse stock split effected on September10, 2018). Neither Ms.Ferrell nor Mr.Kangas have been appointed to any Board committee at this time.

Additional information about Ms.Ferrell and Mr.Kangas is set forth below:

Ms.Ferrell has served as the Executive Chairman and Chief Executive Officer of Glenridge HealthCare Solutions, a national tech-enabled network solutions company, since December2015. From November2014 to November2015, Ms.Ferrell served as an independent healthcare consultant and advisor. She served as Chief Executive Officer of Zest Health, a digital consumer healthcare company, from September2013 to October2014. Ms.Ferrell served as President and Chief Executive Officer of Apollo Health Street, a healthcare solutions company, from May2010 to March2013. She served as Senior Vice President of Provider Contracting and Medical Management of CIGNA Healthcare, a worldwide health services organization, from November2003 to March2009. Ms.Ferrell served as a Senior Manager at Deloitte Consulting, a global consulting firm, from February2000 to November2003. Prior to this, Ms.Ferrell held leadership positions including President of Aetna Healthplans of Florida, Executive Director at Scripps Health and Vice President of Provider Contracting at Prudential HealthCare. Ms.Ferrell also serves as a director of Alacura, a medical transportation benefit management company, Advantum, a healthcare solutions company, and Glenridge HealthCare Solutions. Ms.Ferrell received an M.B.A. from Pepperdine University.

Mr.Kangas served as Global Chairman and Chief Executive Officer of Deloitte, an international public accounting and consulting firm, from 1989 until his retirement in 2000. He also served as the Managing Partner of Deloitte& Touche (USA) from 1989 to 1994.He was elected Managing Partner and Chief Executive Officer of Touche Ross in 1985, a position he held through 1989. Mr.Kangas began his career as a staff accountant at Touche Ross in 1967, where he became a Partner in 1975. Since 2003, he has served as a director of Hovnanian Enterprises,Inc., a publicly traded real estate company, and Tenet Healthcare Corporation, a publicly traded healthcare services company. Since 2013, he has served as a director of Intelsat S.A., a satellite service provider and a foreign private issuer with the Securities and Exchange Commission. He has served as Chairman of the Board of Deutsche Bank USA Corp., a privately held subsidiary of Deutsche Bank AG, since 2016. He formerly served as a director of EDS (2004 to 2009), Allscripts Healthcare Solutions,Inc. (2009 to 2011), Eclipsys Corporation (2005 to 2009),Intuit Inc. (2007 to 2016) and United Technologies Corporation (2009 to 2018).In addition, he is a past Chairman of the Board of the National Multiple Sclerosis Society. He is also a member of Beta Gamma Sigma Directors’ Table and a life trustee of the board of trustees of the Kansas University Endowment Association. In 2010, Mr.Kangas was named by the National Association of Corporate Directors (NACD) to its Directors Hall of Fame. Mr.Kangas received a B.A. in business administration and an M.B.A. from the University of Kansas. Mr.Kangas is a Certified Public Accountant.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.


VIVUS INC Exhibit
EX-99.1 2 a18-37269_1ex99d1.htm EX-99.1 Exhibit 99.1     VIVUS Adds Two New Members to the Board of Directors   Karen Ferrell and Edward A. Kangas Expand VIVUS’ Board to Nine Members   CAMPBELL,…
To view the full exhibit click here

About VIVUS,INC. (NASDAQ:VVUS)

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.

An ad to help with our costs